A carregar...
Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer (NSCLC), is poorly differentiated and highly aggressive. Treatment is limited, and the prognosis is poor. Pembrolizumab is an anti-programmed death (PD)-1 antibody with good efficacy in NSCLC. Recent stud...
Na minha lista:
| Publicado no: | World J Clin Cases |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Inc
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360715/ https://ncbi.nlm.nih.gov/pubmed/32742998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i13.2876 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|